Skip to content
Triangle logo TriangleGet started
← Myeloproliferative Neoplasms

NCT00293384 · STUDY IN CONTEXT

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

exploratory · POSTED

Overall Nausea Controlled

Source null

→

primary · POSTED

No episodes of vomiting and no rescue medication during first 24 hours after cyclophosphamide administration.

Evaluable for response

→

secondary · POSTED

Delayed Vomiting Controlled

Source null

→

secondary · POSTED

Toxicity Grade 3, 4, or 5

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-myeloproliferative-neoplasms
nct id
NCT00293384
trial label
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
4
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-myeloproliferative-neoplasms
    nct id
    NCT00293384
    outcome key
    om-0002
    source section id
    NCT00293384-om-0002
    source outcome index
    2
    endpoint
    Overall Nausea Controlled
    endpoint definition
    Overall Nausea Controlled
    time origin
    at 0-120 hours
    analysis role
    exploratory
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-myeloproliferative-neoplasms
    nct id
    NCT00293384
    outcome key
    om-0000
    source section id
    NCT00293384-om-0000
    source outcome index
    0
    endpoint
    Proportion of Participants With Controlled Acute Vomiting
    endpoint definition
    No episodes of vomiting and no rescue medication during first 24 hours after cyclophosphamide administration.
    time origin
    at 0-24 hours
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Evaluable for response
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-myeloproliferative-neoplasms
    nct id
    NCT00293384
    outcome key
    om-0001
    source section id
    NCT00293384-om-0001
    source outcome index
    1
    endpoint
    Delayed Vomiting Controlled
    endpoint definition
    Delayed Vomiting Controlled
    time origin
    at 25-120 hours
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-myeloproliferative-neoplasms
    nct id
    NCT00293384
    outcome key
    om-0003
    source section id
    NCT00293384-om-0003
    source outcome index
    3
    endpoint
    Toxicity Grade 3, 4, or 5
    endpoint definition
    Toxicity Grade 3, 4, or 5
    time origin
    at 0-120 hours
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-myeloproliferative-neoplasms
    nct id
    NCT00293384
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Aprepitant, Dexamethasone, Cytoxan & Kytril
    regimen
    Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration. Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes. Days 2 \& 3: Aprepitant 80 mg once daily in the morning. Aprepitant: Aprepitant 80mg once daily in the morning on days 2 and 3 Cyclophosphamide: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes Dexamethasone: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration. Granisetron hydrochloride: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
    analyzed count
    35
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00293384-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-myeloproliferative-neoplasms
    nct id
    NCT00293384
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Aprepitant, Dexamethasone, Cytoxan & Kytril
    regimen
    Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration. Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes. Days 2 \& 3: Aprepitant 80 mg once daily in the morning. Aprepitant: Aprepitant 80mg once daily in the morning on days 2 and 3 Cyclophosphamide: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes Dexamethasone: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration. Granisetron hydrochloride: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
    analyzed count
    35
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00293384-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-myeloproliferative-neoplasms
    nct id
    NCT00293384
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Aprepitant, Dexamethasone, Cytoxan & Kytril
    regimen
    Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration. Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes. Days 2 \& 3: Aprepitant 80 mg once daily in the morning. Aprepitant: Aprepitant 80mg once daily in the morning on days 2 and 3 Cyclophosphamide: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes Dexamethasone: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration. Granisetron hydrochloride: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
    analyzed count
    35
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00293384-om-0002#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-myeloproliferative-neoplasms
    nct id
    NCT00293384
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Aprepitant, Dexamethasone, Cytoxan & Kytril
    regimen
    Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration. Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes. Days 2 \& 3: Aprepitant 80 mg once daily in the morning. Aprepitant: Aprepitant 80mg once daily in the morning on days 2 and 3 Cyclophosphamide: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes Dexamethasone: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration. Granisetron hydrochloride: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
    analyzed count
    35
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00293384-om-0003#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-myeloproliferative-neoplasms
    nct id
    NCT00293384
    harm key
    EG000
    source section id
    NCT00293384-ae
    event group key
    EG000
    event group label
    Aprepitant, Dexamethasone, Cytoxan & Kytril
    serious affected
    10
    serious at risk
    35
    other affected
    33
    other at risk
    35
    frequency threshold
    5
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice